A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …

Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of
recurrence. Population pharmacokinetics, pharmacokinetics–pharmacodynamics (anti‐FXa …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …

From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …

Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐
Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Purpose Compared with conventional therapy (enoxaparin followed by warfarin), the direct-
acting oral anticoagulant apixaban is thought to offer similar protection against recurrent …

Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …